首页> 外文OA文献 >Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines that Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase

【2h】

Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines that Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase

机译：吡唑并嘧啶的快速发现和结构 - 活性关系通过sRC激酶抑制有效抑制乳腺癌细胞生长，具有优异的aBL激酶选择性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Fraser, Craig; Dawson, John C; Dowling, Reece; Houston, Douglas R; Weiss, Jason T; Munro, Alison F; Muir, Morwenna; Harrington, Lea; Webster, Scott P; Frame, Margaret C; Brunton, Valerie G; Patton, E Elizabeth; Carragher, Neil O; Unciti-Broceta, Asier;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. SUCI02选择性抑制HER-2/neu受体酪氨酸激酶磷酸化及其对HER-2/neu过表达乳腺癌细胞生长的影响 [J] . 朱孝峰, 刘宗潮, 谢冰芬, 癌症（英文版） . 2003,第008期
2. Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase [J] . Fraser Craig, Dawson John C., Dowling Reece, Journal of Medicinal Chemistry . 2016,第10期

机译：吡唑并嘧啶的快速发现和结构活性关系，可通过SRC激酶抑制作用有效抑制乳腺癌细胞的生长，并具有优于ABL激酶的选择性
3. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. [J] . Finn RS, Dering J, Ginther C, Breast cancer research and treatment. . 2007,第3期

机译：达沙替尼是src和abl激酶的口服活性小分子抑制剂，可选择性抑制体外生长的基础型/“三阴性”乳腺癌细胞系的生长。
4. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro [J] . Richard S. Finn, Judy Dering, Charles Ginther, Breast Cancer Research and Treatment . 2007,第3期

机译：Dasatinib是src和abl激酶的口服活性小分子抑制剂，可选择性抑制体外生长的基础型/“三阴性”乳腺癌细胞系的生长
5. Stilbene analogues as inhibitors of breast cancer Stem cells through P-glycoprotein efflux; A 3D quantitative structure-activity relationship study (Inhibitory activity of stilbenes analogues on breast cancer stem cells) [C] . Anushree Tripathi, Krishna Misra 2016 International Conference on Bioinformatics and Systems Biology . 2016

机译：Stilbene类似物通过P-糖蛋白外排作为乳腺癌干细胞的抑制剂； 3D定量结构-活性关系研究（Stilbenes类似物对乳腺癌干细胞的抑制活性）
6. A Src-Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth and metastasis in vitro and in vivo [D] . Jallal, Houda 2008

机译：SRC-ABL激酶抑制剂，SKI-606，体外和体内阻断乳腺癌侵袭，生长和转移
7. Rapid Discoveryand Structure–Activity Relationshipsof Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growthvia SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase [O] . Craig Fraser, John C. Dawson, Reece Dowling, -1

机译：快速发现与结构-活动关系吡唑并嘧啶可有效抑制乳腺癌细胞生长通过SRC激酶抑制作用具有优于ABL激酶的选择性
8. Discovery of 2((3-Amino-4-methylphenyl)amino)N(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia [O] . -1

机译：发现2（（3-氨基-4-甲基苯基）氨基）N（2-甲基-5-（3-（三氟甲基）苯甲酰氨基）苯基）-4-（甲基氨基）嘧啶-5-甲酰胺（CHMFL-ABL-053 ）作为慢性髓性白血病的有效，选择性和口服的BCR-ABL / SRC / P38激酶抑制剂
9. Effect of Protein Kinase C Modulation with Bryostatin 1 on Paclitaxel-Induced Growth Inhibition and Apoptosis in Human Breast Cancer Cell Lines [R] . Hahm, H. A. 1999

机译：蛋白激酶C调节苔藓抑素1对紫杉醇诱导的人乳腺癌细胞生长抑制和凋亡的影响

Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines that Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase

著录项

引文网络

相似文献

相关主题

期刊订阅